145 related articles for article (PubMed ID: 11254872)
1. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
[TBL] [Abstract][Full Text] [Related]
2. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
Heisterkamp N; Voncken JW; Senadheera D; Gonzalez-Gomez I; Reichert A; Haataja L; Reinikainen A; Pattengale PK; Groffen J
Blood; 2000 Sep; 96(6):2226-32. PubMed ID: 10979970
[TBL] [Abstract][Full Text] [Related]
3. Bcr/Abl associated leukemogenesis in bcr null mutant mice.
Voncken JW; Kaartinen V; Groffen J; Heisterkamp N
Oncogene; 1998 Apr; 16(15):2029-32. PubMed ID: 9591787
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
[TBL] [Abstract][Full Text] [Related]
5. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
[TBL] [Abstract][Full Text] [Related]
6. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice.
Voncken JW; Morris C; Pattengale P; Dennert G; Kikly C; Groffen J; Heisterkamp N
Blood; 1992 Feb; 79(4):1029-36. PubMed ID: 1737087
[TBL] [Abstract][Full Text] [Related]
7. Acute leukaemia in bcr/abl transgenic mice.
Heisterkamp N; Jenster G; ten Hoeve J; Zovich D; Pattengale PK; Groffen J
Nature; 1990 Mar; 344(6263):251-3. PubMed ID: 2179728
[TBL] [Abstract][Full Text] [Related]
8. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
9. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
10. Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
Allen PB; Morgan GJ; Wiedemann LM
Baillieres Clin Haematol; 1992 Oct; 5(4):897-930. PubMed ID: 1308169
[TBL] [Abstract][Full Text] [Related]
11. Loss of Pax5 Exploits Sca1-BCR-ABL
Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
[TBL] [Abstract][Full Text] [Related]
12. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Brain J; Saksena A; Laneuville P
Leuk Res; 2002 Nov; 26(11):1011-6. PubMed ID: 12363470
[TBL] [Abstract][Full Text] [Related]
13. Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Melo JV; Gordon DE; Tuszynski A; Dhut S; Young BD; Goldman JM
Blood; 1993 May; 81(10):2488-91. PubMed ID: 8490164
[TBL] [Abstract][Full Text] [Related]
14. Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
Voncken JW; Griffiths S; Greaves MF; Pattengale PK; Heisterkamp N; Groffen J
Cancer Res; 1992 Aug; 52(16):4534-9. PubMed ID: 1643646
[TBL] [Abstract][Full Text] [Related]
15. Ph-positive leukemia: a transgenic mouse model.
Groffen J; Voncken JW; Kaartinen V; Morris C; Heisterkamp N
Leuk Lymphoma; 1993; 11 Suppl 1():19-24. PubMed ID: 8251894
[TBL] [Abstract][Full Text] [Related]
16. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.
Waldron T; De Dominici M; Soliera AR; Audia A; Iacobucci I; Lonetti A; Martinelli G; Zhang Y; Martinez R; Hyslop T; Bender TP; Calabretta B
Leukemia; 2012 Apr; 26(4):644-53. PubMed ID: 21960247
[TBL] [Abstract][Full Text] [Related]
17. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
18. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Liu J; Wu Y; Arlinghaus RB
Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
[TBL] [Abstract][Full Text] [Related]
19. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
20. Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice.
Griffiths SD; Healy LE; Ford AM; Bennett CA; Voncken JW; Heisterkamp N; Groffen J; Greaves MF
Oncogene; 1992 Jul; 7(7):1391-9. PubMed ID: 1377812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
